Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)
    Meeting Abstract

    Ledermann, J.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.; Clamp, A.; Scambia, G.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Makker, V.; Rasco, D.; Taylor, M.; Dutcus, C.; Shumaker, R.; Schmidt, E. V.; Stepan, D.; Li, D.; Motzer, R. J.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Nivolumab (nivo) in combination with radiotherapy (RT) +/- temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)
    Meeting Abstract

    Lim, M.; Omuro, A.; Vlahovic, G.; Reardon, D. A.; Sahebjam, S.; Cloughesy, T.; Baehring, J.; Butowski, N.; Potter, V.; Zwirtes, R.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A single-arm, phase ii study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC)
    Meeting Abstract

    McArthur, H. L.; Barker, C. A.; Gucalp, A.; Lebron Zapata, L.; Wen, Y. H.; Phung, A.; Wilgucki, M.; Henrich, M.; Arnold, B. B.; Zhang, Z.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N + I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups
    Meeting Abstract

    Escudier, B.; Tannir, N. M.; McDermott, D. F.; Frontera, O. A.; Melichar, B.; Plimack, E. R.; Barthelemy, P.; George, S.; Neiman, V.; Porta, C.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): Safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN)
    Meeting Abstract

    Ferris, R. L.; Gonçalves, A.; Baxi, S. S.; Martens, U. M.; Gauthier, H.; Langenberg, M.; Spanos, W. C.; Leidner, R. S.; Kang, H.; Russell, J.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry
    Meeting Abstract

    Francini, E.; Yip, S.; Ahmed, N. S.; Li, H.; Ardolino, L.; Evan, C. P.; Kaymakcalan, M.; Shaw, G. K.; Kantoff, P.; Taplin, M. E.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors
    Meeting Abstract

    Garcia-Corbacho, J.; Spira, A.; Boni, V.; Feliu, J.; Middleton, M.; Burris, H.; Yang Weaver, A.; Will, M.; Harding, J.; Meric-Bernstam, F.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status
    Meeting Abstract

    Grivas, P.; Plimack, E.; Balar, A. V.; Castellano, D.; O'Donnell, P. H.; Bellmunt, J.; Powles, T.; Hahn, N.; de Wit, R.; Bajorin, D.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)
    Meeting Abstract

    Grob, J. J.; Schadendorf, D.; Wagstaff, J.; Márquez-Rodas, I.; Lebbé, C.; Ascierto, P. A.; Hodi, F. S.; Grossmann, K.; Hassel, J. C.; Walker, D.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save